Lyophilized Drugs Market Witnesses High Growth Owing to Rising Need for Long Shelf-Life Drugs
Lyophilized Drugs Market |
The Lyophilized Drugs Market comprises drugs that have undergone lyophilization or freeze-drying, a process that converts the drug from a liquid to a solid state via drying under partial vacuum. Some key advantages of lyophilization include improved stability at room temperature, ease of storage and transport, and long shelf life without refrigeration up to two years. The rising need for long shelf-life and temperature-stable drugs across various therapeutic areas such as oncology, infectious disease, and autoimmune disorders is driving significant demand for lyophilized drugs.
The global Lyophilized Drugs Market
is estimated to be valued at US$ 366.11 million in 2024 and is expected to
exhibit a CAGR of 5.0% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in the lyophilized drugs are BASF SE, Evonik Industries
AG, Clariant AG, DuPont de Nemours, Inc., Albemarle Corporation, Arkema SA,
Johnson Matthey PLC, Mitsubishi Chemical Corporation, Honeywell International
Inc., Shell Catalysts & Technologies, W. R. Grace & Co., Haldor Topsoe
A/S, Dow Chemical Company, CRI Catalyst Company, and Sud-Chemie India Pvt. Ltd.
(Clariant India Ltd.). Lyophilized injections are expected to witness highest
growth owing to the increasing demand for biologics and vaccines globally. The
Asia Pacific region is likely to offer major opportunities owing to growing
healthcare spending and rising geriatric population in Japan, China, and India.
Key players are focused on capacity expansions and new product launches to
strengthen their presence globally and cater to the growing demand for
long-shelf life biologics and therapeutic drugs across various regions.
Market drivers - The key Lyophilized
Drugs Market Demand driver include the increasing prevalence of chronic
diseases globally necessitating a reliable cold-chain supply for long-shelf
life drugs. The rising investment into biopharmaceutical R&D is also
bolstering demand for freeze-drying to improve the stability of novel
biologics.
Market restraints - The key
challenge is high equipment and manufacturing cost associated with
industrial-scale lyophilization. Lengthy validation and regulatory procedures
also impede faster market adoption. Lack of skilled experts and technicians
with experience in freeze-drying can also restrain market potential in emerging
markets.
Comments
Post a Comment